Medical Countermeasures Smallpox Preparedness Contracts Top $60 Million as U.S. and International Partners Bolster Biodefense StockpilesGlobal Biodefense StaffMarch 25, 2026
Industry News U.S. Government Expands Smallpox Stockpile With $54 Million VIGIV Contract, International Orders Add $6.6 MillionGlobal Biodefense StaffMarch 25, 2026
Medical Countermeasures Mpox Antiviral Clinical Trial Advances as WHO Extends Global EmergencyGlobal Biodefense StaffJuly 17, 2025
Novavax’s Prototype COVID-19 Vaccine Nuvaxovid Receives Full Approval in Singapore Medical Countermeasures October 18, 2023 …
Molecular Diagnostic Test for Six Biothreat Pathogens Receives FDA Clearance Biodetection September 19, 2023 …
Imunon Enters into CRADA for Preclinical Studies of PlaCCine Modality in Preventive Vaccines Against Lassa Virus Industry News August 24, 2023 …
Regeneron Awarded $325M for Development of Next-Gen COVID-19 Monoclonal Antibody Therapy Industry News August 22, 2023 …
RedHill Biopharma Highlights Federal Medical Countermeasure Investments Industry News August 17, 2023 …
BARDA-Supported Anthrax Vaccine Now Approved, Enables Faster Onset to Protection Industry News August 7, 2023 …
BD Gets FDA Clearance for Influenza, RSV, COVID-19 Respiratory Viral Panel Biodetection August 1, 2023 …
908 Devices Launches Remote and Continuous Area Monitoring for Aerosol and Vapor Detection Biodetection July 31, 2023 …
U.S. Invests in mAb Treatment for Ebola with New Award to Emergent BioSolutions Industry News July 31, 2023 …
After Missing the Mark in COVID Trial, Revive Therapeutics Pursues Bucillamine as CBRN Medical Countermeasure Industry News July 28, 2023 …
Smallpox Countermeasures: U.S. Awards $138M to Siga Technologies for TPOXX Industry News July 27, 2023 …
VitriVax Wins DoD Contract to Develop Single-Shot Vaccine for Melioidosis and Glanders Industry News July 19, 2023 …
DARPA Award to Ginkgo Bioworks Aims to Revolutionize Speed of Medical Countermeasure Manufacturing Industry News July 19, 2023 …
Revive Therapeutics Announces Results of Phase 3 Study for Bucillamine in the Treatment of COVID-19 Industry News July 6, 2023 …
